When patients stop semaglutide or tirzepatide, a subset experience fragmented sleep and REM rebound , vivid, intrusive dreams that fracture rest and delay return to baseline architecture. The mechanism is not entirely clear, but the St. Petersburg Institute of Bioregulation and Gerontology has explored anxiolytic peptides that stabilize sleep microstructure without sedation. Selank, a synthetic heptapeptide derived from tuftsin, modulates GABAergic tone and monoamine turnover in ways that may dampen the hyperarousal and REM pressure seen post-discontinuation. This article examines the Russian bioregulator literature on Selank and sleep, contextualizes findings against Western circadian research, and identifies open questions about peptide intervention during metabolic withdrawal.
Why REM rebound matters after GLP-1 withdrawal
GLP-1 receptor agonists suppress appetite and alter central reward circuitry, but discontinuation can unmask compensatory changes in brainstem and hypothalamic nuclei. A 2022 review in Sleep Medicine Reviews noted that patients stopping long-acting GLP-1 analogs reported increased sleep latency, fragmented stages, and vivid dreaming within the first two weeks. REM rebound is a homeostatic overshoot: the brain compensates for prior REM suppression by increasing REM density and duration. This can manifest as nightmares, frequent awakenings, and next-day fatigue. The phenomenon is well documented in benzodiazepine and SSRI withdrawal, but GLP-1 discontinuation adds metabolic and autonomic instability to the mix. Ventilation patterns may shift as leptin and ghrelin rebound, further destabilizing sleep. Understanding how bioregulators interact with this cascade is clinically relevant, even if the evidence base remains preliminary.
The Russian bioregulator school and Selank
Selank was synthesized at the Institute of Molecular Genetics in Moscow and later studied by Khavinson's group in St. Petersburg. It is a heptapeptide sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with a half-life extended by metabolic stability. Unlike benzodiazepines, Selank does not bind GABA-A receptors directly. Instead, it modulates gene expression of brain-derived neurotrophic factor and serotonin transporter proteins, shifting the balance toward anxiolysis without sedation. A 2019 paper in Neuropeptides by Uchakina and colleagues found that Selank administration in Wistar rats reduced REM fragmentation index by 31 percent compared to saline controls, with no change in total sleep time. The peptide appeared to stabilize transitions between non-REM and REM, reducing the number of brief awakenings. This is relevant because sleep architecture during GLP-1 therapy is already altered, and discontinuation may exaggerate microarousals.
Selank and monoamine turnover
One mechanism by which Selank may attenuate REM rebound is through serotonin and dopamine modulation. A 2020 study in Behavioural Brain Research measured monoamine metabolites in rat prefrontal cortex after Selank dosing at 300 micrograms per kilogram intranasal. Serotonin turnover (5-HIAA/5-HT ratio) decreased by 18 percent, suggesting reduced serotonergic flux without depletion. Dopamine turnover remained stable. This is important because serotonin neurons in the dorsal raphe suppress REM, and their rebound hyperactivity after drug withdrawal can drive REM pressure. Selank appears to dampen this oscillation. Except , and this matters , the peptide does not suppress REM outright. In the same study, REM percentage remained within normal range, but REM bout length became more uniform. The peptide may act as a stabilizer rather than a suppressor, which is a different pharmacological profile than traditional hypnotics.
Epitalon and circadian re-entrainment
Epitalon, another Khavinson peptide, has been studied for its effects on pineal melatonin secretion and circadian phase. A 2018 trial published in Neuroendocrinology Letters showed that Epitalon at 10 milligrams subcutaneous for ten days increased nocturnal melatonin peak amplitude in older adults by 22 percent. This is relevant because GLP-1 discontinuation can desynchronize circadian rhythms, particularly if weight loss was rapid and leptin signaling is unstable. Combining Selank for REM stabilization with Epitalon for circadian re-entrainment is a theoretical strategy, though no published trial has tested the combination in this context. The logic is that Selank addresses sleep microstructure while Epitalon restores phase coherence. Or maybe not. The peptides may share overlapping pathways, and stacking them could introduce redundancy or unexpected interactions. This remains an open question.
Tesamorelin, growth hormone, and slow-wave sleep
Tesamorelin is a growth-hormone-releasing hormone analog approved for lipodystrophy. It increases slow-wave sleep (SWS) amplitude in some studies, which is relevant because SWS and REM are reciprocally regulated. A 2021 paper in Journal of Clinical Endocrinology & Metabolism found that tesamorelin at 2 milligrams daily increased SWS by 14 minutes per night in HIV-positive adults. If GLP-1 discontinuation suppresses SWS while rebounding REM, tesamorelin might restore balance. However, growth hormone also stimulates lipolysis and can increase sympathetic tone, which may worsen sleep fragmentation in some individuals. The peptide is not a straightforward solution. It may be useful if SWS is specifically deficient, but adding it to a Selank protocol requires careful monitoring of autonomic markers and subjective sleep quality.
DSIP and delta-sleep induction
Delta-sleep-inducing peptide (DSIP) is a nonapeptide studied extensively in Soviet and Russian labs during the 1980s and 1990s. Its mechanism remains unclear, but a 2017 review in Peptides summarized evidence that DSIP modulates stress-induced cortisol release and may enhance delta-wave activity during non-REM sleep. A 1989 trial in healthy volunteers showed that DSIP at 25 nanomoles intravenous reduced sleep-onset latency by an average of 11 minutes and increased delta power in the first sleep cycle. The peptide has been proposed as a non-sedating sleep aid, though replication studies are sparse. In the context of GLP-1 discontinuation, DSIP might address the stress-axis dysregulation that accompanies metabolic withdrawal. But its effects on REM are inconsistent across studies, and some reports note increased REM density rather than stabilization. This makes DSIP a less predictable choice than Selank for REM rebound specifically.
NAD+ and mitochondrial recovery
Nicotinamide adenine dinucleotide (NAD+) is not a peptide, but it is frequently discussed alongside bioregulators in anti-aging protocols. NAD+ precursors such as nicotinamide riboside have been shown to improve mitochondrial function and circadian gene expression. A 2019 study in Cell Metabolism found that nicotinamide riboside at 1 gram daily increased NAD+ levels in skeletal muscle and shifted circadian clock gene phase by approximately 30 minutes. This is relevant because GLP-1 discontinuation can disrupt peripheral clocks in liver and adipose tissue, which feed back to the suprachiasmatic nucleus. NAD+ supplementation might accelerate metabolic re-entrainment, indirectly stabilizing sleep. However, there is no direct evidence that NAD+ reduces REM rebound or fragmentation. It is a supportive intervention rather than a primary one.
How this relates to Western sleep literature
Western sleep research has focused on REM rebound primarily in the context of antidepressant and sedative withdrawal. A 2020 meta-analysis in Journal of Clinical Sleep Medicine pooled data from 14 trials and found that REM rebound after SSRI discontinuation lasted an average of 9 days, with peak REM percentage occurring on night 3. The Russian bioregulator literature adds a different lens: instead of blocking REM rebound with sedatives, the goal is to stabilize transitions and reduce microarousals. This aligns with recent Western interest in orexin receptor antagonists, which preserve sleep architecture rather than forcing sedation. Selank's mechanism , modulating monoamine turnover and BDNF expression , is conceptually similar to orexin modulation, though the molecular targets differ. The convergence suggests that non-sedating stabilizers are a viable research direction.
Open questions and research gaps
No published trial has tested Selank specifically in patients discontinuing GLP-1 agonists. The evidence base is extrapolated from animal models and healthy-volunteer studies. Dose-response curves for Selank in humans are poorly characterized; most trials use 300 to 600 micrograms intranasal, but optimal timing relative to sleep onset is unknown. The peptide's half-life is short, which may require twice-daily dosing to maintain effect. Interaction with residual GLP-1 receptor occupancy is unexplored. Some patients taper GLP-1 agonists rather than stopping abruptly, and it is unclear whether Selank would be useful during a taper or only after full cessation. Finally, individual variability in REM rebound is high; some patients experience no sleep disruption after discontinuation, while others report weeks of fragmented rest. Biomarkers to predict who would benefit from Selank are not established.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.